AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 302 min read$BIIB

Biogen (BIIB) Receives a Buy from TD Cowen

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB) with a $250.00 price target. Biogen's shares closed at $244.05. The company reported Q3 revenue of $2.8B and a net loss of $20.6M, down from last year's $2.45B revenue and $466.5M profit. Insider sentiment is negative, with recent sales by directors.

Original reporting
theglobeandmail.com
Published Oct 30, 2026, 9:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 9:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Biogen (BIIB) Receives a Buy from TD Cowen — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$BIIBBullishMed
01

Why it matters

The new Buy rating and $250 target provide a catalyst for short‑term price appreciation, though insider sales may temper enthusiasm.

02

Market read

Analyst upgrade on a mid‑cap biotech with fresh earnings data offers a modest trading opportunity.

03

What to watch

Potential headwinds from upcoming regulatory reviews of Biogen's pipeline are not reflected in the rating.

Relevance 7/10Novelty 7/10Timing: today

Background

Biogen released its Q3 earnings, showing revenue growth but a GAAP loss, prompting analyst coverage updates.

Company-level read

Ticker impact

$BIIBBullishHigh confidence
Context

TD Cowen maintained a Buy on Biogen and set a $250 price target after the company reported Q3 revenue of $2.8 B and a GAAP loss, indicating fresh analyst endorsement.

Expected impact

likely upward pressure as investors price in the new $250 target.

Evidence & confidence

The rating and target are fresh, tied to the latest earnings release, and the stock closed near $244, leaving room for a modest rally.

Market effects

Sector

The upgrade may lift sentiment across the broader biotech sector.

Regional

US biotech stocks could see modest gains in early trading.

Global

Limited to investors tracking US-listed biotech equities.

Counterpoint

What could challenge this read

The recent insider selling and negative insider sentiment could signal underlying concerns despite the upgrade.

Key entities

  • company
    Biogen

    US‑listed biotech (NASDAQ:BIIB) reporting Q3 results.

  • analyst
    TD Cowen

    Equity research firm issuing the Buy rating.

Read at source← All news

Related articles

OCT 29
$BIIBHighAI 8/10

Freedom Broker raises Biogen stock price target on strong results

Freedom Broker raised its price target on Biogen (BIIB) to $275 from $255, citing strong quarterly results and resilient portfolio performance. The stock is near its 52-week high of $258.78. Biogen reported adjusted earnings of $2.62 per share on revenue of $2.8 billion, exceeding expectations. Several analysts have revised earnings upwards and raised price targets.

investing.com2 min
OCT 29
$BIIBHighAI 9/10

Biogen Q3 Revenue Surges to $2.8 Billion as New Drugs Deliver; Company Raises Full-Year EPS Floor

Biogen (BIIB) reported Q3 revenue of $2.8B, up 11% YoY, beating estimates. Adjusted EPS of $2.62 also surpassed expectations. The company raised its full-year EPS guidance to $12.20-$13.00. Growth products, including rare disease and Alzheimer's drugs, drove revenue growth, while MS drugs declined. R&D and SG&A expenses increased significantly. Biogen expects mid-single-digit revenue growth in 2026.

finance.biggo.com3 min
OCT 29
$BIIBMedAI 8/10

Biogen Inc (BIIB) (Q3 2026) Earnings Call Highlights: Revenue Climbs 11% as Growth

Biogen Inc (BIIB) reported Q3 2026 revenue up 11% to $3.2B, but GAAP EPS was a loss of $0.14 due to acquisition-related charges. VUMERITY revenue declined 11% YoY, while Apellis acquisition increased OPEX by 27%. Biogen updated its PREVAIL trial design to a one-year eGFR endpoint. Management discussed market potential for felzartamab in AMR and litifilimab in SLE/CLE, and noted strong uptake of IQLIK and SPINRAZA high dose.

finance.yahoo.com3 min
OCT 28
$BIIBHighAI 8/10

Biogen Q3 Earnings Call Highlights

Biogen reported Q3 earnings, highlighting a 23% YoY increase in SPINRAZA revenue to $461M, driven by patient conversions. LEQEMBI revenue rose 67% to $202M, while SKYCLARYS increased 34% to $178M. TYSABRI revenue grew 1% to $437M, and VUMERITY declined 11% to $192M. Biogen raised its 2026 EPS guidance to $12.20-$13.00 and expects key pipeline data readouts in the coming months.

finance.yahoo.com2 min